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Expression of the major histocompatibility complex
(MHC) class II-associated invariant chain (Ii) is required
for efficient and complete presentation of antigens by
MHC class II molecules and a normal immune response.
The Ii gene is generally co-regulated with the MHC class
II molecules at the level of transcription and a shared
SXY promoter element has been described. This report
defines the proximal promoter region of Ii which may
regulate Ii transcription distinct from MHC class II. In
vivo genomic footprinting identified an occupied, imper-
fect CCAAT box and an adjacent GC box in the proximal
region. These sites are bound in Ii-ositive cell lines and
upon interferon-g induction of Ii transcription. In con-
trast, both sites are unoccupied in Ii-egative cell lines
and in inducible cell lines prior to interferon-g treat-
ment. Together these two sites synergize to stimulate
transcription. Independently, the transcription factor
NF-Y binds poorly to the imperfect CCAAT box with a
rapid off rate, while Sp1 binds to the GC box. Stabiliza-
tion of NF-Y binding occurs upon Sp1 binding to DNA. In
addition, the half-life of Sp1 binding also increased in
the presence of NF-Y binding. These findings suggest a
mechanism for the complete functional synergy of the
GC and CCAAT elements observed in Ii transcription.
Furthermore, this report defines a CCAAT box of imper-
fect sequence which binds NF-Y and activates transcrip-
tion only when stabilized by an adjacent factor, Sp1.
One of the central steps in elicitation of an immune response
is the presentation of foreign antigenic peptides by the major
histocompatibility complex (MHC)1 class II molecules on the
surface of cells (1, 2). Recognition of the peptidezMHC class II
complex by the T-cell receptor on class II-restricted T lymphoid
cells leads to activation of the T cells and the initiation of the
immune response (3, 4). Binding of peptides to the class II
molecules is regulated in part by the MHC class II-associated
invariant chain (Ii) protein (5, 6). The Ii is an integral mem-
brane protein which associates with class II a/b molecules in
the endoplasmic reticulum (7, 8). This association has multiple
affects on class II molecules, all of which optimize the binding
and presentation of foreign peptides derived from the extracel-
lular environment (reviewed in Refs. 9, 10). The Ii also appears
to play a role in targeting the class II molecules to endosomal or
endosomal-like compartments where peptide is bound (11–14).
The critical role of Ii was demonstrated in mutant mice lacking
a functional Ii gene (15, 16). MHC class II function was im-
paired resulting in inefficient antigen presentation and a defi-
ciency in CD41 T cells.
The tight functional association of Ii and class II is reflected
in their coordinate transcriptional regulation. Both molecules
are only expressed in a select group of cells including B cells,
activated human T cells, thymic epithelial cells, and macro-
phages (17–19). Ii and class II are also coordinately induced by
interferon-g (IFN-g) in several cell types including macro-
phages and brain glial cells (20–23). The Ii promoter and the
class II promoters share a common DNA motif, S/X/Y, which
interacts with at least three distinct transcription factors (4,
24–26). Several studies have clearly demonstrated that this
motif is responsible for both the constitutive and IFN-g-in-
duced coordinate regulation (27–30). In class II promoters, this
motif is located proximal to the TATA box and is generally
sufficient for transcriptional activation. In contrast, the Ii pro-
moter has over 170 base pairs (bp) between the TATA box and
the S/X/Y motif. There are several cases of differential regula-
tion between Ii and class II genes (17, 18, 31, 32). The addi-
tional Ii promoter sequences between the S/X/Y and TATA
domains may harbor elements mediating the discordant tran-
scription. In the murine Ii promoter, an NF-kB site has been
identified which mediates basal and TNFa induction of Ii tran-
scription (33). In addition, promoter deletion analysis impli-
cated a GC box as important for the basal activity of the murine
gene (30). Recently, two NF-kB sites have been characterized at
position 2172 and 2118 base pairs of the human Ii promoter
(34). The function of these elements is dependent on cell type-
specific differences in the binding of NF-kB subunits. Despite
these studies, little is known about the Ii proximal promoter
and the factors bound there which may be required for tran-
scription as well as potentially mediating the effects of the
distal S/X/Y motif.
The Y box of the S/X/Y motif is an inverted CCAAT site which
binds the heteromeric transcription factor NF-Y (also known as
CBF, CP1, and YEBP) (35–38). NF-Y is clearly distinct from
the other known CCAAT box-binding proteins, CTF/NF-1 and
C/EBP. NF-Y is composed of an A, B, and C subunit of 42, 36,
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and 40 kDa, respectively (39, 40). NF-Y is highly conserved
through evolution (41). The yeast transcription factors HAP3,
HAP2, and HAP5 are homologues of the A, B, and C subunits,
respectively, and are functionally interchangeable in a DNA
binding assay (42). In addition to MHC class II promoters,
NF-Y-binding sites are found in many unrelated promoters; e.g.
HSV-tk (37), collagen (36), and albumin (43). Typically the
binding sites are located in the proximal promoter region be-
tween 260 and 280 base pairs upstream of the transcription
initiation site (44). Functional analysis has also shown that
NF-Y can be important in transcription reinitiation as well as
in activation, suggesting a role in basal transcription (43, 45).
In the MHC class II promoters, NF-Y also functions to sta-
bilize and/or recruit additional transcription factors to the
S/X/Y complex. In vitro, NF-Y and the X box-binding protein,
RFX, co-stabilize binding to their DNA sites (46). Furthermore,
in vivo mutation of the NF-Y-binding site abrogates factor
binding to the upstream X1 and X2 sites (47). In addition, NF-Y
requires that the DNA stereospecifically align the X and Y
boxes for activation (48). NF-Y has also been studied at the
serum albumin promoter and in that context functions syner-
gistically with C/EBP to activate transcription (43). The inter-
action between these factors partially destabilizes NF-Y bind-
ing but results in a large synergistic increase in the formation
of stable preinitiation complexes. These studies of NF-Y sug-
gest that although found in many different promoters, its mode
of function may depend upon the local environment of that
specific promoter.
In this report we now describe the in vivo characterization of
the elements and factors involved at the proximal promoter of
the human Ii gene. Through the use of in vivo genomic foot-
printing, two adjacent binding sites with homology to a GC box
and an imperfect CCAAT box are identified. The GC and
CCAAT elements act synergistically to promote Ii transcription
and are bound by the transcription factors Sp1 and NF-Y,
respectively. NF-Y and Sp1 bind cooperatively at the Ii pro-
moter to mediate, at least in part, the observed functional
synergy. Thus, maximal Ii transcription requires the action of
two NF-Y factors; one in the distal S/X/Y motif and one de-
scribed here in a cooperative binding complex with Sp1 in the
proximal promoter. These findings describe a mechanism of
transcriptional activation by the ubiquitous transcription fac-
tor NF-Y and define a new promoter region regulating Ii ex-
pression.
EXPERIMENTAL PROCEDURES
DNA Constructs—The invariant chain promoter, chloramphenicol
acetyltransferase (CAT) reporter gene construct, 790IiCAT, contains
the human Ii promoter sequences from 11 to 2790 base pairs relative
to the transcription initiation site (49). Mutant constructs were derived
by oligonucleotide-directed, site-specific mutagenesis as described pre-
viously (50). The construct 790IimtGC changed the sequence at 274 to
265 bp from 59-TGGGCGGAGT-39 to 59-TGtttGGAGT-39. The construct
790IimtYprox changed the sequence at 250 to 242 bp from 59-CGAAT-
CAGAT-39 to 59-CGAcgCtcAT-39. The double mutant construct,
790IimtGC/Yprox, contained the changes in both sites as described for
the single mutants. All mutations were confirmed by DNA sequencing.
Cell Culture, Transient Transfection, and CAT Aassay—Raji is a
human Epstein-Barr virus-positive Burkitt’s lymphoma cell line that
expresses high levels of Ii gene and MHC class II antigens. H9 (HuT78)
was derived from a human T cell lymphoma and also expresses high
levels of Ii gene and MHC class II antigens. Jurkat is a T lymphoblas-
toid cell line which does not express Ii or MHC class II genes. These
cells were grown in RPMI 1640 supplemented with 8% fetal calf serum
and 2 mM glutamine. The human glioblastoma multiform cell line,
U105-MG, which was previously referred to as U373-MG in this labo-
ratory was grown in McCoy’s 5A supplemented with 10% fetal calf
serum and 2 mM glutamine. Interferon-g induction of U105-MG cells
used 500 units/ml and was generously provided by Biogen (Cambridge,
MA). Transient transfections of the Raji cells were performed by elec-
troporation as described previously (51). The transfectants were har-
vested 24 h following electroporation. Expression of the transiently
transfected reporter genes was assayed by quantitating chloramphen-
icol acetyltransferase activity in cell extracts as described previously
(51). CAT activity was resolved on thin layer chromatography plates
and quantitated with a Molecular Dynamics PhosphorImager (Sunny-
vale, CA).
In Vivo Footprinting—In vivo methylation of cells and DNA prepa-
ration were as described by Pfeifer et al. (52). The ligation-mediated,
polymerase chain reaction amplified in vivo genomic footprinting was
as originally described by Mueller and Wold (53) and modified by
Wright and Ting (54). The primer set utilized to reveal the Ii proximal
promoter, upper strand is: UPP1, 59-ATTGTTGGAGATAAGGTCG-39;
UPP2, 59-ATGACTGGCTTCTGATCTTCCCGACAGC; UPP3, 59-ACTG-
GCTTCTGATCTTCCCGACAGCTCCTG-39. The primer set utilized to
reveal the Ii proximal promoter, lower strand is: LPP1, 59-GCCCA-
GAAACAAGTGATGAG-39; LPP2, 59-GGATCGTGCTGGCCTTTCTAC-
CTGC-39; LPP3, 59-GGATCGTGCTGGCCTTTCTACCTGCCTG-39.
Nuclear Extract Preparation and Gel Shift Analysis—Nuclear ex-
tracts were prepared according to Dignam et al. (55) from Raji cells
grown in suspension to a density of 8 3 105 cells/ml. Gel shift analysis
was performed as described previously (56). The wild type Ii oligonu-
cleotide, IiGC/Yprox, spanned from 282 to 232 bp of the promoter
relative to the transcription initiation site. The sequence is shown in
Fig. 1C. The IiYprox oligonucleotide contains a mutation of the GC box
and is 59-CATCTACCAAGTGtttGGAGTGGCCTTCTGTGGACGAATC-
AGATTCCTCTCCAG-39. The Ii GC oligonucleotide contains a mutation
in the Y-proximal site and is 59-CATCTACCAAGTGGGCGGAGTGGC-
CTTCTGTGGACGAcgCtcATTCCTCTCCAG-39. The DRA Y box oligo-
nucleotide is 59-ATTTTTCTGATTGGCCAAAGATTT-39. The consensus
Sp1-binding site oligonucleotide is 59-GTCACCGGGGCGGGGCGGT-
CAC-39. The DRA octa oligonucleotide is 59-AGAGTAATTGATTTGC-
ATTTTAATGGTCAG-39. The TAATGARAT consensus OTF-1-binding
site oligonucleotide was derived from the HSV IE45 promoter and is
59-TTCACGCGGTAATGAGATGGGTT-39. Antibody supershift experi-
ments were performed by preincubating 1 mg of antibody for 2 h on ice
with each binding reaction prior to the addition of the DNA probe. The
NF-YA and NF-YB antibodies have been reported previously (47). The
Sp1 and NF-kB-p50 antibodies were purchased from Santa Cruz Inc.
(Santa Cruz, CA).
Relative DNA Binding Affinity and Half-life Determination—The
relative DNA binding affinity constants of the Sp1zNF-Y complex com-
pared to either Sp1 or NF-Y alone was calculated from EMSA compe-
tition gels as described previously in detail (57). Briefly, gel shift bind-
ing reactions with increasing amounts of specific competitor DNA (0–
500-fold molar excess) were allowed to come to equilibrium and then
separated by non-denaturing gel electrophoresis. The amount of com-
plexed and free probe was measured by PhosphorImage analysis. As-
suming, where P is the DNA-binding protein and C is the proteinzDNA
complex, [DNA] .. [P] then [DNA] 5[DNA]
t
5 0 at all times and the
affinity constant of the DNA binding reaction can be described by 1/Kaff
5 [C]/[P]*[DNA]. Rearranging the formula reveals that a plot of 1/[C]
versus 1/[DNA] will define 21/Kaff as the x intercept. Using the crude
nuclear extract conditions described in this report the Kaff will be
affected, however, since the conditions are the same for each assay and
do not vary the Kaff should be valid relative to each other. Half-lives of
the DNA binding activities were calculated as described previously (58)
except the same specific oligonucleotides described for gel shift analysis
were used as the competitors as indicated in the figure legend. Briefly,
a 5-fold scale up of the standard EMSA reaction was allowed to come to
equilibrium. A greater than 1000-fold molar excess of the competitor
contained in a volume of less than 4% of the binding reaction was added
to the binding reaction. Aliquots of the binding reaction were then
loaded onto a continuously electrophoresing EMSA gel at 0, 1, 2, 4, 8,
15, and 25 min after addition of the competitor. The free and all shifted
complexes were quantitated by PhosphorImage analysis. Half-lives
were determined from a plot of the fraction of total probe in the specific
complex at times during the competition divided by the fraction of total
probe in the specific complex at time 0 min versus time. The formula is
[C1]
t
5x/[C11C21Cn1F]t5x divided by [C1]t 5 0/[C11C21Cn1F]t 5 0,
where C is the complex concentration, F is the free probe concentration,
and t is the time of competition. The half-life of either factor alone was
determined from EMSA reactions with the IimtGC or IimtYprox probes
which only bind one of the factors to simplify the calculations.
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RESULTS
In Vivo Genomic Footprinting Reveals an Occupied GC Box
and an Imperfect CCAAT Box—Several studies by our labora-
tory and others have characterized transcriptional elements
present in the distal promoter region of the Ii gene. However,
little is known about the identity or requirement for proximal
elements. We directly addressed this question by mapping the
DNA sequences occupied in intact cells by in vivo genomic
footprinting. In vivo footprinting allows the visualization of
protein-DNA interactions on endogenous genes in the more
physiologically relevant intact cell. Fig. 1 displays the foot-
prints for the first 90 base pairs of the Ii promoter in cell lines
consitutively positive for Ii expression, Raji and H9 and an
Ii-negative cell line, Jurkat. Two very clear domains of contacts
were detected in the B lymphoblastoma cell line, Raji and the T
lymphoblastoid cell line H9 (Fig. 1, A and B, lanes 1–4 and
summarized in Fig. 1C). The contacts in both of these cell lines
and in another Ii-expressing B cell line, Namalwa (data not
shown) were identical. Five protections and two enhancements
on the upper strand were clustered over a sequence with high
homology to a consensus GC box. The single guanine residue on
the lower strand of this GC box was also protected (Fig. 1B). In
addition, two guanine residues flanking the GC box were
weakly protected. Downstream of the GC box region a second,
weaker clusters of contacts are visible. There is a weak protec-
tion at position 256 and a strong protection at 250 on the
upper strand. On the lower strand there is a strong protection
at 251 and a second weak protection at 239. These contacts
partially overlap with a imperfect NF-Y/CCAAT box-binding
site. A consensus NF-Y/CCAAT box has previously been char-
acterized in the distal region of the Ii promoter and is referred
to as the Y box. Thus we named the imperfect, proximal NF-
Y/CCAAT homology, Y-proximal (Y-prox). The weak degree of
in vivo protection of the Y-proximal site is consistent with
FIG. 1. In vivo protein-/DNA interac-
tions at the Ii gene proximal pro-
moter reveal an occupied GC box and
imperfect NF-Y site. A, In vivo footprint
analysis of the upper strand of the Ii prox-
imal promoter. Cont., control in vitro
methylated deproteinized DNA; In vivo,
in vivo methylated DNA. Open arrows,
protections; solid arrows, enhancements.
Weak interactions are depicted by arrow-
heads. The functional elements as defined
in this report are indicated by brackets on
the left. The Raji B cell line and the H9 T
cell line constitutively express Ii, and the
contact points at the GC box and Y-prox-
imal site are the same. The Ii-negative
Jurkat T cell line only displayed a single
weak protection at position 250. B, lower
strand in vivo footprint analysis. Lane
markings are the same as in panel A. Five
protections were detected across the GC
box and Y-proximal site in the constitu-
tively expressing Raji and H9 cell lines.
No contacts were detected in Ii negative
Jurkat cell line. C, sequence of the Ii prox-
imal promoter and summary of the in vivo
contact points. The functional elements
are indicated by shaded boxes and the
arrows and arrowheads are as in panels A
and B.
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previous in vivo footprint analysis of other consensus NF-Y-
binding sites (49, 54). In addition, protection of the Y-proximal
adenine residues at position 245, 248, and 249 was detectable
in Raji cells by a modified in vivo footprinting protocol (data not
shown, 59). Analysis of the Ii-negative, T lymphoblastoid cell
line Jurkat did not detect any protein-DNA interactions at the
GC box and Y-proximal elements on the lower strand and only
a single weak protection on the upper strand (Fig. 1, A and B,
lanes 5 and 6). Our previous in vivo analysis of the distal
portion of the Ii promoter also revealed it to be unoccupied in
Jurkat cells. The single protection in Jurkat cells could indicate
an extremely weak interaction at the Y-proximal site or more
likely reflect an alteration of the DNA structure in that area,
since the rest of the promoter is unoccupied. A similar bare
promoter was observed for the MHC class II promoter DRA in
Jurkat cells even though the transcription factors are available
in the nucleus (54). These results suggest that class II and
Ii-negative cells may prevent transcription of these genes by
blocking the accessibility of transcription factors to the promot-
ers. Furthermore, the class II and Ii genes may use a common
mechanism to block accessibility despite their location on dif-
ferent chromosomes.
Ii gene transcription is strongly induced by IFN-g in a num-
ber of non-lymphoid cell types. In the glioblastoma cell line
U105-MG, the induction is mediated through a 5–6-fold in-
crease in the rate of Ii gene transcription (34). In vivo footprint
analysis of the Ii proximal promoter in U105-MG cells revealed
no protein-DNA interactions prior to IFN-g induction (Fig. 2).
Four h after the addition of IFN-g, protections are clearly
visible at the GC box and Y-proximal site. The contacts are
identical to those observed in the Raji and H9 cells. A similar
pattern of interaction was observed at 18 and 48 h post-induc-
tion. This region of the Ii promoter has not been implicated in
the IFN-g response; rather two upstream elements, the ISRE
and S/X/Y domain, appear to mediate the induction (27, 29, 60).
Analysis of those IFN-g-responsive elements as well as the two
NF-kB sites displayed in vivo occupancy only after IFN-g treat-
ment (34, 49). Interestingly, protection at these distal elements
did not become maximal until 24 or 48 h post-induction (see
“Discussion”). This indicates that the entire Ii promoter is
shielded from transcription factor binding in the uninduced
state, and IFN-g treatment relieves this repression.
The GC Box and Y-proximal Site Synergistically Activate Ii
Transcription—We addressed the functional importance of the
newly identified in vivo binding sites by preparing site-specific
mutants of the recognition sequences and assaying the effect on
transcription from the Ii promoter. The GC box was altered by
changing the core sequence to three successive T residues. This
mutation blocks Sp1 binding to GC boxes as shown previously
(61) and below. Four residues were altered in the Y-proximal
site which eliminated all potential homology to CCAAT boxes.
Each of the mutations were assayed in the context of the
790-base pair Ii promoter fused to the CAT reporter gene.
These constructs were first transfected into the constitutively
high expressing Raji B cell line. Transcription from the Ii
promoter with a mutated GC box is dramatically lowered to
24% of wild type (Fig. 3). A similar loss in activity is detected
from the Ii promoter with a mutated Y-proximal site. Signifi-
cantly, no further reduction in transcription is observed when
the both the GC box and Y-proximal site are mutated in one
construct (mtGC/Yprox). This finding suggests these elements
can not activate independently of each other in the Ii promoter,
since neither site alone has activity greater than the double
mutant construct. The remaining transcriptional activity is
likely to be driven from the distal SXYmotif, which alone in the
class II DRA gene is sufficient to promote high levels of expres-
sion. The Ii double mutant construct was slightly but reproduc-
ibly higher than the single GC box mutation. This may indicate
that the Y-proximal site in the absence of the GC box represses
transcription. The effect of these mutations on the IFN-g in-
ducibility of Ii transcription was examined by transfection into
U105-MG cell line. All of the mutant constructs were strongly
induced by IFN-g treatment, although the basal level of expres-
sion was lowered (data not shown). This finding provides evi-
dence that these elements are not involved in the IFN-g induc-
tion pathway. However, in the constitutively expressing cells
the GC box and Y-proximal sites are critical for maximal tran-
scription and display complete synergy in activation.
Sp1 Binds at the GC Box and NF-Y Binds at the Imperfect
CCAAT Box—In vitro binding studies were utilized to identify
the factors interacting with the in vivo identified GC box and
Y-proximal site. Oligonucleotides containing both binding sites
and corresponding to the region between 232 and 285 of the Ii
promoter were assayed by EMSA. Titrating increasing
amounts of Raji B-cell nuclear extract into the binding reaction
with a constant amount of probe resolved four specific binding
activities, labeled A-D (Fig. 4A, lanes 1–4). An identical pattern
was detected when nuclear extracts from a second B cell line,
FIG. 2. Induction of Ii expression by interferon-g induces in
vivo protein-DNA interactions at the Ii proximal promoter. The
glioblastoma cell line, U105-MG, was treated with 500 units/ml recom-
binant IFN-g and examined by in vivo footprint analysis at the times
indicated above each lane. Lane markings are as described in Fig. 1. At
time 0 h, no contacts were detected. Interactions at both the GC box and
Y-proximal site were clearly detectable at 4 h and continued for 18 and
48 h. The interactions were indistinguishable from those detected in the
constitutively expressing B and T cell lines.
FIG. 3. The Ii GC box and Y-proximal site synergize to activate
transcription. The wild type (WT) Ii promoter construct contains 790
base pairs of the promoter fused to the CAT reporter gene. Site-specific
mutation of the GC box (mtGC), Y-proximal site (mtYprox), or both
(mtGC/Yprox) are derived from the wild type parent construct as de-
scribed under “Experimental Procedures.” Constructs were transiently
transfected into the Raji B cell line and assayed by CAT activity. The
results are normalized to one for expression from the wild type con-
struct. Each bar represents data from seven independent experiments,
and the S.E. is indicated by the error bars.
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Namalwa, were used (data not shown). All of the bands in-
crease in intensity as the amount of nuclear extract is in-
creased. However, the slowest migrating band, D, accumulates
most rapidly. At the lowest protein concentration band D is the
least abundant complex, but at the highest protein concentra-
tion band D represents a significant portion of the total shifted
probe. This pattern is consistent with band D representing a
multimeric complex composed of two or more of the faster
migrating complexes. The specificities of the complexes were
identified by oligonucleotide competition. Self-competition with
the Ii sequence containing both the GC box and Y-proximal
sites (lane 5) abrogated all binding except for the weak nonspe-
cific band (n.s.). Bands D and B were competed by an Ii Y-
proximal oligonucleotide (lane 6) while the Ii GC box oligonu-
cleotide competed for the D, C, and A bands (lane 7). An
oligonucleotide mutated in both the GC and Y-proximal sites
failed to compete for any band (lane 8). Therefore, binding at
the Y-proximal site is related to the D and B bands while
binding at the GC box is related to the D, C, and A bands. This
finding is consistent with the D band representing specific,
simultaneous binding at both the GC box and Y-proximal site.
The GC box has strong homology to a Sp1-binding site. Com-
petition with a Sp1 consensus binding site oligonucleotide re-
moves bands D, C, and A (lane 9). The resulting pattern is
identical to competition with the Ii GC box oligonucleotide and
further suggests Sp1 is binding at the Ii GC box. Competition
with a high affinity OTF-2-binding site from the MHC class II
DRA promoter had no effect on any of the complexes (lane 10).
Although the Y-proximal site is divergent at the highly con-
served second C residue of the CCAAT box, the remainder of
the sequence conforms to an 11-bp NF-Y consensus. The con-
sensus was derived from 17 different published NF-Y-binding
sites (Table I). The MHC class II DRA Y box is a high affinity
NF-Y-binding site and was used in EMSA competition to access
the relationship between the Y-proximal binding activity and
NF-Y (Fig. 4B). Competition of the Ii GC/Yprox oligonucleotide
probe with the DRA Y box eliminated the D and B bands (lane
3). This pattern of competition is identical to competition with
the Ii Y-proximal site as shown in Fig. 4A, lane 6. The unre-
lated DRA octa oligonucleotide did not compete for any of the
bands. The Y-proximal site also has weak homology to the
OTF-1 binding consensus TAATGARAT. However, none of the
Ii-specific bands were competed for by a TAATGARAT oligonu-
cleotide (lane 5). An identical pattern of competition was ob-
served when a probe corresponding to the DRA Y box was used
(lanes 6–10). Both Ii GC/Yprox and DRA Y box oligonucleotides
competed the NF-Y band. Neither the DRA octa or TAATGA-
RAT competed for the band. Together, the competition results
suggest that NF-Y interacts at the Y-proximal site. Further-
more, both NF-Y and Sp1 can bind simultaneously to the Ii
promoter as evidenced by the D band.
A direct test for the presence of NF-Y and Sp1 on the Ii
promoter is available through the use of antibodies specific for
the two transcription factors. Specific antibodies or preimmune
sera are added to the EMSA binding reaction and then resolved
by gel electrophoresis. A specific antibody interaction either
diminishes the gel shift band (blocking) or shifts the complex
higher in the gel (supershift). We first tested the antibodies on
the wild type Ii probe (Fig. 5, lanes 1–5). The preimmune sera
has no effect on any of the complexes. However, the antisera
specific for the A subunit of NF-Y results in a supershifted
band concomitant with a decrease in the intensity of the D and
B bands. This is consistent with the association of the D and B
bands with binding at the Y-proximal site. The anti-Sp1 anti-
body also produced a supershifted complex and diminished the
D and C bands. However, the B band was unaffected. This is
also consistent with the D and C bands representing GC box
binding. An unrelated antibody specific for NF-kB-p50 did not
effect any of the bands. The antibodies were also assayed on the
NF-Y complex derived from the DRA Y box probe (lanes 6–10).
Only the antibody specific for NF-YA subunit supershifted the
NF-Y complex. To simplify the gel shift-antibody pattern, the
same experiment was done with gel shift probes mutated in one
or the other binding sites. As shown in lanes 11–15, when the
Y-proximal binding activity is present alone only the NF-YA
FIG. 4. In vitro binding to the Ii proximal promoter detects
complexes with the GC box, the Y-proximal site, and both to-
gether. A, EMSA analysis with the wild type Ii probe, IiGC/Yprox (232
to 285 bp). Shaded triangle indicates increasing amounts of Raji nu-
clear extract (0.2–2 mg) added to the binding reaction and the shaded
rectangle represents a constant 1 mg of nuclear extract. Specific com-
plexes are labeled A-D while n.s. indicates the nonspecific band. Oligo-
nucleotide competitors are indicated above lanes 5–10 and are described
under “Experimental Procedures.” B, EMSA competition analysis dem-
onstrates that the complex binding to the Y-proximal site is related to
NF-Y. The wild type Ii probe (IiGC/Yprox) is used in lanes 1–5, and the
high affinity NF-Y site DRA Y-box is used for lanes 6–10.
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and B antibodies recognize this band (lanes 12 and 13). A probe
that contains only the GC box binding activity forms both the A
and C bands (lane 16). The antibody specific for Sp1 supershifts
the C band but not the A band (lane 19). This confirms the
identity of the C band as Sp1, while the much less abundant A
band is an immunologically unrelated GC box-binding protein.
Combined, the gel shift and antibody reactivity clearly defines
NF-Y binding at the Y-proximal site. Furthermore, this indi-
cates Sp1 is the predominant GC box-binding protein, although
at this point a role for the A band protein cannot be excluded.
Sp1 and NF-Y Cooperatively Bind to the Ii Promoter by
Increasing Their DNA-binding Half-lives—Functional synergy
has been reported for a number of different promoters. Several
mechanisms have been proposed to account for these synergis-
tic effects, including direct and indirect physical interaction
between transcription factors and with the basal transcription
machinery. We have initially tested whether the synergism
between NF-Y and Sp1 is reflected in cooperative binding to
their DNA sites. The relative affinity of the proteins for their
DNA-binding sites was approximated by EMSA competition
assays (see “Experimental Procedures” and Ref. 57 for calcula-
tions). This approach utilizes the EMSA to quantitate the
amount of complex formed in the presence of increasing
amounts of specific competitor DNA. The affinity constant can
be estimated from a plot of 1/[complex] versus 1/[DNA] (for
assumptions, see “Experimental Procedures”). The value ob-
tained is affected by the complex assay mixture including the
crude nuclear extract and nonspecific competitor DNAs which
cannot be corrected for. However, under fixed assay conditions
the values obtained should be valid with respect to each other.
No change was detected in the relative affinity constants for
binding of either Sp1 or NF-Y alone compared to the Sp1zNF-Y
complex (data not shown). We next compared the off-rates of
the two proteins alone and in a complex together. In this
TABLE I
A partial list of genes containing NF-Y-binding sites
Analysis of eukaryotic promoters reveals the presence of the CCAAT element in many genes. The sequence surrounding the CCAAT site and the
location relative to the start site of transcription is presented. rev. indicates sequence is in the reverse orientation. The consensus sequence shown
includes all nucleotides represented in greater than 20% of the NF-Y-binding site.
Gene CCAAT/flank sequence Location Refs.
Human Ii Y box AGCCAATGGGA 2205 27, 28
Mouse Ii Y box AGCCAATGGGA 2198 29, 30
MHC DRA GGCCAATCAGA 267 (rev.) 47
Mouse Ea AACCAATCAGA 252 (rev.) 83
Interleukin-4 GGCCAATCAGC 2107 (rev.) 84
b-Actin GGCCAATCAGC 291 85
a-Globin AGCCAATGAGC 270 86
HSV-tk CGCCAATGACA 282 (rev.) 37
a1(I)collagen AGCCAATCAGA 296 (rev.) 36
a2(I)collagen CACCAATGGGA 280 (rev.) 36
Roas sarcoma virus-long term repeat CACCAATCGGC 2129 (rev.) 87
Lipoprotein lipase AGCCAATAGGT 265 88
Albumin AACCAATGAAA 288 43
Tyrosine amino trans. AACCAATAGCA 275 89
Thrombospondin 1 GGCCAATGGGC 262 90
MDR-1 AGCCAATCAGC 275 (rev.) 73




Human Ii Y-proximal GACGAATCAGA 251 this report
FIG. 5. EMSA-antibody supershift analysis identifies NF-Y interacting at the Y-proximal site and Sp1 at the GC box. The antibodies
used are indicated above each lane. 2, no antibody; PI, preimmune antiserum. The probes used are marked above each gel. Other markings are
as described in Fig. 4.
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analysis, EMSA-binding reactions with DNA probes containing
either the Ii GC box or Y-proximal site or both together were
allowed to reach equilibrium. Specific competitors in excess of
1000-fold were then added. Aliquots of the binding reaction
were subsequently loaded onto a continuously electrophoresing
gel at 0, 1, 2, 4, 8, 15, and 25 min after competitor addition. The
intensities of the specific bands were quantitated by Phosphor-
Image analysis and plotted as the intensity of the band after
competition for a given time over the intensity of the band prior
to competition (see “Experimental Procedures” for details). The
time at which only 50% of the complex is remaining is calcu-
lated as the half-life and thus is a measure of the stability of the
intaction after the complex is formed. As shown in Fig. 6A,
NF-Y binding to the Y-proximal site of Ii is very unstable with
a half-life of only 1.7 min. However, when NF-Y binds to the Ii
promoter in conjunction with Sp1 binding the half-life of NF-Y
increases 4.5-fold. To examine whether the increased stability
would be significant, a comparison was made to the consensus
NF-Y site from the DRA promoter (Fig. 6B). Similar half-lives
were detected for both the functional DRA-NF-Y interaction
and the Ii-NF-YzSp1 complex. Examination of Sp1 binding to
the Ii GC box also revealed a stabilization of binding when in
an Sp1zNF-Y complex (Fig. 6C). The half-life of Sp1 binding
alone was 3.2 min. When present together with NF-Y, the
half-life of Sp1 increased to approximately 3-fold. These find-
ings indicate that both factors are stabilized when binding at
adjacent sites and suggests a mechanism by which the imper-
fect Y-proximal element can function as an NF-Y-binding site.
Thus, DNA binding cooperativity is one of the underlying
sources for the functional synergy observed between Sp1 and
NF-Y.
DISCUSSION
Control of Ii gene transcription plays a critical role in the
presentation of antigens by MHC class II molecules and the
maintenance of a normal immune response. This report now
defines a new region of the Ii promoter required for expression
of this gene. Examination of the in vivo occupancy of the Ii
promoter in constitutively expressing cell lines identified a
bound GC box and imperfect CCAAT box (Y-proximal) at posi-
tions 274 and 253, respectively, relative to the transcription
initiation site. Only 11 base pairs or one helical turn of the
DNA separate these two recognition sites. In addition, binding
at the TATA box at position 224 was detected when an alter-
native in vivo footprinting protocol was utilized to reveal con-
tacts at adenine residues (data not shown). Combined with our
previous studies (34, 49), these observations now complete the
in vivo footprint analysis of the entire 300-base pair Ii pro-
moter. There are eight elements clearly bound in vivo; TATA
box (224 bp), Y-proximal (253 bp), GC box (274 bp), ISRE
(296 bp), kB-1 (2118 bp), kB-2 (kB-2 bp), Y (2207 bp), and X
(2236 bp). Additionally, the S element (2260 bp) has been
defined functionally but does not display interaction contacts in
vivo. This is consistent with the related S element in the class
II DRA promoter which also did not show in vivo contacts
(54, 62).
The GC box and Y-proximal sites were occupied in both B
and T cell lines which constitutively express Ii. However, nei-
ther site was bound in the Ii-negative Jurkat T cell line. The
lack of in vivo binding occurs despite the presence of the trans-
acting factors Sp1 and NF-Y in the nuclei of these cells, as
detected by in vitro binding assays (34, 54).2 Furthermore,
none of the elements within the 300-bp Ii promoter are occu-
pied in vivo in the Ii-negative cell line. However, when the Ii
promoter is transiently introduced into these cells, it displays a
significant level of transcriptional activity. This finding sug-
gests a higher order inhibition of DNA binding at the endoge-
nous Ii promoter, potentially at the level of chromatin reorga-
nization. This is consistent with the nuclease hypersensitivity
studies done on many genes, which demonstrated that inactive
genes are often found in condensed, nuclease-resistant regions
of the chromatin (63–65). Interestingly, the functionally re-
lated class II DRA gene promoter is also unoccupied and not
expressed in the Jurkat cell line. Although the class II genes
2 K. L. Wright, unpublished observations.
FIG. 6. The DNA binding half-lives of NF-Y and Sp1 are stabi-
lized when both factors are complexed with the DNA together.
A, off-rate analysis of NF-Y independently bound to the Ii Y-proximal
site, t1⁄2 5 1.7 min (squares), or bound as a complex with Sp1 at the Ii
proximal promoter, t1⁄2 5 7.5 min (circles). B, comparison of NF-Y
binding stability at the consensus DRA-Y box, t1⁄2 5 6.0 min (squares),
and the Ii NF-YzSp1 complex, t1⁄2 5 7.5 min (circles). C, off-rate analysis
of Sp1 bound either independently to the Ii GC box, t1⁄2 5 3.2 min
(squares) or in a complex with NF-Y, t1⁄2 5 8.9 min (circles). Where the
horizontal line at 50 intersects the plot indicates the calculated half-life
for that plot. Values were determined from PhosphorImage analysis of
EMSA competition gels as described under “Experimental Procedures”
and are plotted as the percent of complex shifted over the initial com-
plex formed before competition versus the time of competition. Band D
was quantitated for the half-life of Sp1 and NF-Y after competition with
either the GC box or a consensus Y-box, respectively (see lane 1, Fig. 5
for example gel prior to competition). Band B of the Ii-Y-proximal probe
was quantitated for the half-life of NF-Y alone (see lane 11, Fig. 5 for
example of gel prior to competition). Band C of the Ii GC probe was
quantitated for the half-life of Sp1 alone (see lane 16, Fig. 5 for example
of gel prior to competition). Band “NF-Y” of the DRA-Y box probe was
quantitated for the half-life of NF-Y on the consensus Y box (see lane 6,
Fig. 5 for example gel prior to competition). Each point is the average of
at least three independent experiments and the S.E. in indicated by the
error bars.
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are located on a separate chromosome from Ii, a similar mech-
anism may be responsible for the inaccessibility of these pro-
moters in non-expressing cells.
Interferon-g is a potent inducer of Ii and class II transcrip-
tion (23, 66–68). In the IFN-g-inducible cell line U105-MG, the
Ii proximal promoter elements GC and Y-proximal sites are
unoccupied prior to the induction. IFN-g treatment up-regu-
lates binding at both proximal elements by 4 h, and binding
continues at 18 and 48 h after addition IFN-g. Loading of the
proximal elements appears to occur prior to loading at the
distal elements. The distal X and Y boxes display only the very
weak beginnings of interaction at 4 h but by 24 h showmaximal
binding (49). Loading at the negative Ii element kB-1 appears
to be delayed even further, until 48 h. This finding suggests
that interactions at the Y-proxmal site and/or the GC box occur
first and may be required to open the promoter for additional
factor binding. Thus, the Ii promoter minimizes basal level
expression by preventing binding of the transacting factors in
the uninduced state. This is in direct contrast to the class II
DRA gene in which all elements are bound prior to IFN-g
induction in this cell line (54). Treatment with IFN-g then
induces an up-regulation of the weak binding activity at the X
box of the DRA S/X/Y domain to a strong interaction. The Ii
promoter also utilizes an S/X/Y domain for the IFN-g response
(27, 29) and to a lesser degree an ISRE element (60). Thus, the
induction pathway for Ii and class II are likely to be highly
related. However, the mechanism by which the Ii promoter
remains unoccupied until IFN-g treatment is unclear. In vivo
analysis of several other promoters has revealed situations
analogous to both the all or none effect observed for Ii and the
limited effect detected for class II DRA (53, 69–71). It is some-
what surprising to find two coordinately regulated genes in-
voking different mechanisms. Interestingly, an in vivo study of
the class II DRA promoter demonstrated a central requirement
for NF-Y in the loading of the promoter (47). Stable introduc-
tion of a DRA promoter construct with a mutated Y/CCAAT box
blocked in vivo binding at all promoter elements in the IFN-g-
induced U105-MG cells. In contrast mutation of the other pro-
moter elements S, X1, and X2 only has a local effect on binding
in vivo. The findings from that study implicated the transcrip-
tion factor NF-Y binding to the Y/CCAAT box as critical for
recruitment of the other promoter factors and/or opening the
chromatin structure across the promoter region. This has po-
tentially important implications for the Ii promoter since two
NF-Y-binding CCAAT boxes are present in this promoter, the
distal Y box of the S/X/Y domain and the Y-proximal element.
It will be interesting to determine if one or both of these
elements modulate accessibility to the Ii promoter.
Synergistic activation by two distinct transcription factors is
becoming a common phenomenon and several different mech-
anisms have been reported (see Ref. 72 and references within).
This report defines a synergistic activation of Ii transcription
by Sp1 bound at the GC box and NF-Y bound at the Y-proximal
site. Neither site was capable of activating Ii transcription in
the absence of the other site. However, together they formed a
strong transcriptional activator. At least one basis for their
synergy is that NF-Y binds to the Y-proximal element with a
very short half-life. Sp1 also binds to the Ii GC box with a short
half-life. Stabilization of both NF-Y and Sp1 binding occurs
when Sp1 and NF-Y bind the Ii promoter together. This sug-
gests that in vivo Sp1 and NF-Y may only bind cooperatively to
the Ii promoter and thus are completely dependent on each
other to activate transcription. In vivo footprint analysis of
mutant Ii promoters indicates both sites must be present for
binding to occur at either site.3 Interestingly, the human mul-
tidrug resistance gene MDR has a similar arrangement of GC
box and CCAAT box in its proximal promoter (73). These ele-
ments were shown to functionally synergize4 although the
mechanism has not been investigated. The MDR CCAAT box
matches the consensus NF-Y sequence (Table I), however,
stabilization of DNA binding may also play a role in MDR
activation.
A number of studies have described cooperative interactions
of Sp1 with other factors, but not NF-Y. Examples include
OTF-1 (74), C/EBP (75), NF-kB (76), Ets (77), E2, YY1 (78, 79),
and Sp1 (80, 81). In at least one case a direct physical interac-
tion between Sp1 and the E2 factor was clearly demonstrated
even in the absence of an E2 DNA-binding site (82). In addition,
Sp1 can multimerize and thereby synergistically activate tran-
scription (80). However, in most cases the mechanisms are less
well defined. NF-Y has been described in two distinct cooper-
ative interactions. The MHC class II DRA promoter has an
NF-Y-binding site which must be stereospecifically aligned
with the X box to function (48). Reith et al. (46) recently dem-
onstrated that stable binding of NF-Y and the X box factor RFX
required a cooperative interaction between the two proteins.
NF-Y also binds in the serum albumin promoter adjacent to a
C/EBP site. The binding of both proteins is required to promote
stable preinitiation complex formation (43). Interestingly, in
this case NF-Y DNA binding is weaker in the complex with
C/EBP than when alone. Clearly these studies reinforce the
hypothesis that synergy can occur through many different
mechanisms. In particular, NF-Y appears to have multiple
activating functions which are dependent on the local promoter
environment.
In conclusion, maximal transcription from the Ii promoter
requires a GC box and NF-Y site proximal to the TATA box.
These sites function in a synergistic mannar, and it is shown
that cooperativity in DNA binding is at least one mechanism
underlying the synergy. An additional outcome of this study is
the identification of a functional, imperfect NF-Y-binding site
that would be undetected in homology searches for the consen-
sus core sequence CCAAT or CAAT. This raises the potential
for an even greater usage of NF-Y in promoters that do not
have a classical CCAAT box. Finally, the Ii gene exhibits all or
none in vivo binding across the promoter in response to IFN-g
induction. With the previous observations that NF-Y can con-
trol access to the DRA promoter in vivo (47), it will be impor-
tant to determine if NF-Y plays a similar role for Ii. This could
have broad implications for the regulation of multiple genes
with an NF-Y/CCAAT box.
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